Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as the case may be. For purposes of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares (excluding treasury shares, if any) issued and outstanding.
Appears in 127 contracts
Sources: Warrant Agreement (Can-Fite BioPharma Ltd.), Warrant Agreement (Can-Fite BioPharma Ltd.), Pre Funded Warrant Agreement (Can-Fite BioPharma Ltd.)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as the case may be. For purposes of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares (including Ordinary Shares underlying ADSs, but excluding treasury shares, if any) issued and outstanding.
Appears in 53 contracts
Sources: Security Agreement (Biodexa Pharmaceuticals PLC), Securities Agreement (Biodexa Pharmaceuticals PLC), Securities Agreement (Biodexa Pharmaceuticals PLC)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as the case may be. For purposes of this Section 3, the number of Ordinary Shares or ADSs, as applicable, deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares or ADSs, as applicable, (excluding treasury shares, if any) issued and outstanding.
Appears in 27 contracts
Sources: Placement Agent Warrant (Purple Biotech Ltd.), Warrant to Purchase American Depositary Shares (BioLineRx Ltd.), Warrant Agreement (Purple Biotech Ltd.)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADSa share, as the case may be. For purposes of this Section 3, the number of Ordinary Shares or ADSs, as applicable deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares or ADSs, as applicable (excluding treasury shares, if any) issued and outstanding.
Appears in 8 contracts
Sources: Security Agreement (Addex Therapeutics Ltd.), Security Agreement (Addex Therapeutics Ltd.), Security Agreement (Addex Therapeutics Ltd.)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADSa share, as the case may be. For purposes of this Section 3, the number of ADSs and/or Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of ADSs or Ordinary Shares Shares, as applicable (excluding treasury shares, if any) issued and outstanding.
Appears in 8 contracts
Sources: Warrant to Purchase American Depositary Shares (SOS LTD), Warrant Agreement (SOS LTD), Warrant to Purchase American Depositary Shares (SOS LTD)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as the case may be. For purposes of this Section 3, the number of Ordinary Shares or ADSs deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares or ADSs, as applicable, (excluding treasury shares, if any) issued and outstanding.
Appears in 7 contracts
Sources: Placement Agent Warrant (RedHill Biopharma Ltd.), Warrant Agreement (RedHill Biopharma Ltd.), Warrant Agreement (RedHill Biopharma Ltd.)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADS, ADS as the case may be. For purposes of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares (including Ordinary Shares underlying ADSs, but excluding treasury shares, if any) issued and outstanding.
Appears in 6 contracts
Sources: Security Agreement (Kazia Therapeutics LTD), Security Agreement (Kazia Therapeutics LTD), Warrant Amendment and New Warrant Issuance Agreement (Kazia Therapeutics LTD)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADSADS or Ordinary Share, as the case may be. For purposes of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares (excluding treasury shares, if any) issued and outstandingoutstanding (including Ordinary Shares represented by ADSs but excluding Ordinary Shares held by the Depositary for future sale and issuance).
Appears in 5 contracts
Sources: Security Agreement (ASLAN Pharmaceuticals LTD), Securities Agreement (ASLAN Pharmaceuticals LTD), Security Agreement (ASLAN Pharmaceuticals LTD)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as the case may be. For purposes of this Section 3, the number of Ordinary Class A Shares or ADSs, as applicable deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Class A Shares or ADSs, as applicable (excluding treasury shares, if any) issued and outstanding.
Appears in 5 contracts
Sources: Warrant Agreement (BIT Mining LTD), Warrant Agreement (BIT Mining LTD), Warrant Agreement (BIT Mining LTD)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADSa share, as the case may be. For purposes of this Section 3, the number of Ordinary Shares ADSs deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares ADSs (excluding treasury shares, if any) issued and outstanding.
Appears in 5 contracts
Sources: Securities Purchase Agreement (Bionomics Limited/Fi), Purchase Warrant (BiondVax Pharmaceuticals Ltd.), Purchase Warrant (BiondVax Pharmaceuticals Ltd.)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as the case may be. For purposes of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares (including Ordinary Shares underlying ADSs but excluding treasury shares, if any) issued and outstanding.
Appears in 4 contracts
Sources: Warrant Agreement (Nano Dimension Ltd.), Warrant Agreement (Nano Dimension Ltd.), Warrant Agreement (Nano Dimension Ltd.)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th 1/2000th of an ADS, as the case may be. For purposes of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares (excluding treasury shares, if any) issued and outstanding.
Appears in 3 contracts
Sources: Security Agreement (Akari Therapeutics PLC), Securities Agreement (Akari Therapeutics PLC), Securities Agreement (Akari Therapeutics PLC)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADSa share, as the case may be. For purposes of this Section 3, the number of ADSs or Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of ADSs or Ordinary Shares (excluding treasury shares, if any) issued and outstanding.
Appears in 2 contracts
Sources: Underwriting Agreement (Carbon Zero Technologies International Inc.), Underwriting Agreement (Intchains Group LTD)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as the case may be. For purposes of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Ordinary Shares (including Ordinary Shares underlying ADSs, but excluding treasury shares, if any) issued and outstanding.
Appears in 2 contracts
Sources: Warrant Agreement (Tiziana Life Sciences PLC), Representative’s Warrant Agreement (Tiziana Life Sciences PLC)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADSa share, as the case may be. For purposes of this Section 3, the number of ADSs or Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of ADSs or Ordinary Shares (excluding treasury sharesADSs or Ordinary Shares, if any, as applicable) issued and outstanding.
Appears in 2 contracts
Sources: Purchase Agreement (Kazia Therapeutics LTD), Warrant Agreement (Kazia Therapeutics LTD)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADSa share, as the case may be. For purposes of this Section 3, the number of Ordinary Shares and/or ADSs deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares and/or ADSs (excluding treasury shares, if any) issued and outstanding.
Appears in 2 contracts
Sources: Warrant Agreement (SOS LTD), American Depositary Share Agreement (Yoshitsu Co., LTD)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADSa share, as the case may be. For purposes of this Section 3, the number of ADSs or Ordinary Shares Shares, as applicable, deemed to be issued and outstanding as of a given date shall be the sum of the number of ADSs or Ordinary Shares (excluding treasury sharesADSs or Ordinary Shares, if any, as applicable) issued and outstanding.
Appears in 2 contracts
Sources: Prefunded Ads Purchase Warrant (RedHill Biopharma Ltd.), Warrant Agreement (RedHill Biopharma Ltd.)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an Ordinary Share or ADS, as the case may be. For purposes of this Section 3, the number of Ordinary Shares or ADSs deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares (excluding treasury shares, if any) or ADSs issued and outstanding.
Appears in 1 contract
Sources: Warrant (Belite Bio, Inc)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADSa share, as the case may be. For purposes of this Section 3, the number of Ordinary Shares or ADS deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares (excluding treasury shares, if any) or ADS issued and outstanding.
Appears in 1 contract
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADSOrdinary Share, as the case may be. For purposes of this Section 3, the number of Ordinary Shares or ADSs, as applicable deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares or ADSs, as applicable (excluding treasury shares, if any) issued and outstanding.
Appears in 1 contract
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADSa share, as the case may be. For purposes of this Section 3, the number of Ordinary Shares ADS deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares ADS (excluding treasury shares, if any) issued and outstanding.
Appears in 1 contract
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as the case may be. For purposes of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares (including Ordinary Shares underlying the Warrant ADSs, but excluding treasury shares, if any) issued and outstanding.
Appears in 1 contract